Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (111-120 of 520) with videos related to

Pageof 52
Sort By:
JACC. Heart Failure|August 22, 2025
Capturing Totality of Treatment Effects: A Model-Free Approach to Analyzing Multiple Event-Time Data From Heart Failure StudiesStephanie Armbruster, Zachary R McCaw, Karola Jering, et al.
European Journal of Heart Failure|November 10, 2021
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCATJoão Pedro Ferreira, Jiankang Liu, Brian L Claggett, et al.
JACC. Heart Failure|March 20, 2026
Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical TrialsZachary R McCaw, Stephanie Armbruster, Lu Tian, et al.
Circulation|March 27, 2002
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factorsFrank M Sacks, Andrew M Tonkin, Timothy Craven, et al.
European Journal of Heart Failure|January 10, 2018
Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database InitiativeJoão Pedro Ferreira, Kevin Duarte, Marc A Pfeffer, et al.
The New England Journal of Medicine|January 7, 2005
C-reactive protein levels and outcomes after statin therapyPaul M Ridker, Christopher P Cannon, David Morrow, et al.
Journal of Diabetes and Its Complications|April 28, 2021
NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trialMagnus O Wijkman, Brian L Claggett, Marc A Pfeffer, et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
Circulation|September 17, 2003
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationshipGary F Mitchell, Yves Lacourcière, Jean-Pascal Ouellet, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose, Hicham Skali, Nagesh Anavekar, et al.
Pageof 52

Showing results (111-120 of 520) with videos related to

Sort By:
Pageof 52
JACC. Heart Failure|August 22, 2025
Capturing Totality of Treatment Effects: A Model-Free Approach to Analyzing Multiple Event-Time Data From Heart Failure StudiesStephanie Armbruster, Zachary R McCaw, Karola Jering, et al.
European Journal of Heart Failure|November 10, 2021
Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCATJoão Pedro Ferreira, Jiankang Liu, Brian L Claggett, et al.
JACC. Heart Failure|March 20, 2026
Using Days Alive and Out of Hospital as the Study Endpoint in Cardiovascular Heart Failure Clinical TrialsZachary R McCaw, Stephanie Armbruster, Lu Tian, et al.
Circulation|March 27, 2002
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factorsFrank M Sacks, Andrew M Tonkin, Timothy Craven, et al.
European Journal of Heart Failure|January 10, 2018
Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database InitiativeJoão Pedro Ferreira, Kevin Duarte, Marc A Pfeffer, et al.
The New England Journal of Medicine|January 7, 2005
C-reactive protein levels and outcomes after statin therapyPaul M Ridker, Christopher P Cannon, David Morrow, et al.
Journal of Diabetes and Its Complications|April 28, 2021
NT-proBNP versus routine clinical risk factors as a predictor of cardiovascular events or death in people with dysglycemia - A brief report from the ORIGIN trialMagnus O Wijkman, Brian L Claggett, Marc A Pfeffer, et al.
Archives of Internal Medicine|August 13, 2008
The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) programHertzel C Gerstein, Karl Swedberg, Jonas Carlsson, et al.
Circulation|September 17, 2003
Determinants of elevated pulse pressure in middle-aged and older subjects with uncomplicated systolic hypertension: the role of proximal aortic diameter and the aortic pressure-flow relationshipGary F Mitchell, Yves Lacourcière, Jean-Pascal Ouellet, et al.
Journal of the American Society of Nephrology : JASN|August 25, 2006
Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarctionPowell Jose, Hicham Skali, Nagesh Anavekar, et al.
Pageof 52